Department of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu, 704-701, Korea.
Arch Pharm Res. 2019 Jan;42(1):88-100. doi: 10.1007/s12272-018-01103-y. Epub 2019 Jan 10.
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis via death receptor (DR) 4 or DR5 preferentially in cancer cells, and not in normal cells with relatively high decoy receptor expression. However, multiple mechanisms in cancer cells induce resistance to DRs-mediated apoptosis. Therefore, understanding of molecular mechanisms for resistance to DRs-mediated apoptosis can find the strategy to increase sensitivity. Although multiple proteins are involved in resistance to DRs-mediated apoptosis, we focus on modulation of DR5 to overcome resistance. Here, we discuss regulation of DR5 expression or activation by epigenetic modification, transcription factor at the transcriptional levels, micro RNA and RNA-binding proteins at the post-transcriptional levels, and ubiquitination and glycosylation at the post-translational levels. In addition, we also mention about relationship between localization of DR5 and death signaling activation. The purpose of this review is to help understand relationship between regulatory mechanisms of DR5 and resistance to TRAIL or DRs-targeted agonist monoclonal antibodies, and to develop innovative anti-cancer therapies through regulation of DR5 signaling.
肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)通过死亡受体(DR)4 或 DR5 优先诱导癌细胞凋亡,而不会诱导正常细胞凋亡,因为正常细胞表达相对较高的诱饵受体。然而,癌细胞中多种机制诱导对 DR 介导的细胞凋亡的抗性。因此,了解对 DR 介导的细胞凋亡的抗性的分子机制可以找到增加敏感性的策略。尽管有多种蛋白质参与对 DR 介导的细胞凋亡的抗性,但我们专注于调节 DR5 以克服抗性。在这里,我们讨论了表观遗传修饰、转录因子在转录水平、microRNA 和 RNA 结合蛋白在转录后水平以及翻译后水平的泛素化和糖基化对 DR5 表达或激活的调节。此外,我们还提到了 DR5 定位与死亡信号激活之间的关系。本综述的目的是帮助理解 DR5 的调节机制与 TRAIL 或 DR 靶向激动型单克隆抗体的抗性之间的关系,并通过调节 DR5 信号来开发创新的抗癌疗法。